[Antitumor effects of different combinations of oridonin, bleomycin A5 and nitrocaphane].
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D004224:Diterpenes / Q000008:administration & dosage; D045786:Diterpenes, Kaurane; D004357:Drug Synergism; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D012510:Sarcoma 180 / Q000188:drug therapy*
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004224:Diterpenes; D045786:Diterpenes, Kaurane; D009588:Nitrogen Mustard Compounds; C011959:oridonin; D001761:Bleomycin; C008634:nitrocaphane; C025703:bleomycetin